Epithalon

Epithalon is one of the smallest bioactive peptides studied in ageing research: just four amino acids, alanine, glutamic acid, aspartic acid and glycine (C14H22N4O9, 390.4 g/mol). It was designed at the St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson's group, after decades of work with epithalamin, a polypeptide extract of bovine pineal glands that had shown anti-ageing effects in animals.

The idea behind Epithalon is simple: identify the shortest synthetic sequence that reproduces what the pineal extract does, then make it in pure, defined form. The pineal gland controls the body's melatonin rhythm, and its activity declines with age, so Epithalon became a research tool for asking whether supporting pineal function can slow biological ageing.

How such a small peptide works is still being mapped. The leading proposal is that Epithalon enters cells and interacts with specific regions of chromatin, switching on genes such as hTERT, the catalytic subunit of telomerase. Telomerase rebuilds telomeres, the protective caps at chromosome ends that shorten with every cell division and are one of the best-known biomarkers of ageing.

Benefits of Epithalon reported in research

The pivotal cell study was published in 2003 in the Bulletin of Experimental Biology and Medicine. Khavinson, Bondarev and Butyugov added Epithalon to human fetal fibroblasts that normally have no telomerase activity. The cells began expressing the catalytic telomerase subunit, showed measurable enzyme activity and lengthened their telomeres, suggesting that the peptide can reactivate a silenced telomerase gene in ordinary body cells.

For two decades that finding came mainly from one research school, which made independent replication important. In 2025, Al-dulaimi and colleagues at Brunel University London published in Biogerontology a quantitative study in normal fibroblasts, normal epithelial cells and two breast cancer cell lines. In normal cells, Epithalon lengthened telomeres in a dose-dependent way by raising hTERT mRNA and telomerase activity. In the cancer lines, telomere lengthening ran instead through the ALT (alternative lengthening of telomeres) pathway, a distinction the authors highlight for future safety research.

Whole-organism data come from rodents and primates. Anisimov and colleagues (Biogerontology, 2003) followed 54 treated and 54 control female mice from 3 months of age until natural death. Epithalon did not change food intake, body weight or average lifespan, but it extended maximum lifespan by 12.3 %, reduced chromosome damage by 17.1 % and cut leukaemia incidence 6-fold. In rhesus monkeys, Goncharova et al. (Experimental Gerontology, 2005) showed that Epithalon raised night melatonin and improved glucose and insulin handling in old animals only, pointing to a restorative rather than stimulating effect.

Taken together, the evidence is strongest in cells and animals. Human data exist mainly as small studies from the originating Russian institute, so Epithalon is best viewed as a well-characterised research peptide for telomere, pineal and longevity biology.